Your browser doesn't support javascript.
loading
High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege.
Ager, Casey R; Boda, Akash; Rajapakshe, Kimal; Lea, Spencer Thomas; Di Francesco, Maria Emilia; Jayaprakash, Priyamvada; Slay, Ravaen B; Morrow, Brittany; Prasad, Rishika; Dean, Meghan A; Duffy, Colm R; Coarfa, Cristian; Jones, Philip; Curran, Michael A.
Afiliação
  • Ager CR; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Boda A; Immunology Program, University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, Texas, USA.
  • Rajapakshe K; Center for Translational Immunology, Columbia University Irving Medical Center, New York, New York, USA.
  • Lea ST; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Di Francesco ME; Immunology Program, University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, Texas, USA.
  • Jayaprakash P; Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Slay RB; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Morrow B; Immunology Program, University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, Texas, USA.
  • Prasad R; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Dean MA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Duffy CR; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Coarfa C; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Jones P; Immunology Program, University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, Texas, USA.
  • Curran MA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
J Immunother Cancer ; 9(8)2021 08.
Article em En | MEDLINE | ID: mdl-34341132
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Células Supressoras Mieloides / Imunoterapia / Proteínas de Membrana Limite: Animals / Humans / Male Idioma: En Revista: J Immunother Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Células Supressoras Mieloides / Imunoterapia / Proteínas de Membrana Limite: Animals / Humans / Male Idioma: En Revista: J Immunother Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Reino Unido